Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD
June 23rd 2025
Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.